These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16139565

  • 1. Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells.
    Planavila A, Sánchez RM, Merlos M, Laguna JC, Vázquez-Carrera M.
    Biochim Biophys Acta; 2005 Sep 15; 1736(2):120-7. PubMed ID: 16139565
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes.
    Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázquez-Carrera M.
    Cardiovasc Res; 2005 Mar 01; 65(4):832-41. PubMed ID: 15721863
    [Abstract] [Full Text] [Related]

  • 3. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy.
    Planavila A, Laguna JC, Vázquez-Carrera M.
    J Biol Chem; 2005 Apr 29; 280(17):17464-71. PubMed ID: 15728586
    [Abstract] [Full Text] [Related]

  • 4. Atorvastatin attenuates TNF-α-induced increase of glucose oxidation through PGC-1α upregulation in cardiomyocytes.
    Gao F, Ni Y, Luo Z, Liang Y, Yan Z, Xu X, Liu D, Wang J, Zhu S, Zhu Z.
    J Cardiovasc Pharmacol; 2012 Jun 29; 59(6):500-6. PubMed ID: 22343369
    [Abstract] [Full Text] [Related]

  • 5. The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells.
    Palomer X, Álvarez-Guardia D, Davidson MM, Chan TO, Feldman AM, Vázquez-Carrera M.
    PLoS One; 2011 Jun 29; 6(5):e19724. PubMed ID: 21625432
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Effect of atorvastatin on advanced glycation end products induced monocyte chemoattractant protein-1 expression in cultured human endothelial cells].
    Xu SH, Wang KF, Xu CS, Xie LD.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jun 29; 39(6):512-7. PubMed ID: 21924076
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.
    Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M.
    Circ Res; 2003 Mar 21; 92(5):518-24. PubMed ID: 12600885
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.
    Barroso E, Eyre E, Palomer X, Vázquez-Carrera M.
    Biochem Pharmacol; 2011 Feb 15; 81(4):534-43. PubMed ID: 21146504
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S, Grabeklis S, Hanck T, Sergeeva M, Reiser G.
    Mol Pharmacol; 2009 Aug 15; 76(2):414-24. PubMed ID: 19483106
    [Abstract] [Full Text] [Related]

  • 15. [Atorvastatin inhibits macrophage-derived foam cell formation by suppressing the activation of PPARγ and NF-κB pathway].
    Cheng X, Liu X, Song L, He Y, Li X, Zhang H.
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jun 15; 34(6):896-900. PubMed ID: 24968852
    [Abstract] [Full Text] [Related]

  • 16. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4.
    Sanguino E, Roglans N, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC.
    Br J Pharmacol; 2005 Aug 15; 145(7):853-61. PubMed ID: 15912134
    [Abstract] [Full Text] [Related]

  • 17. Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.
    Coll T, Alvarez-Guardia D, Barroso E, Gómez-Foix AM, Palomer X, Laguna JC, Vázquez-Carrera M.
    Endocrinology; 2010 Apr 15; 151(4):1560-9. PubMed ID: 20185762
    [Abstract] [Full Text] [Related]

  • 18. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
    Li J, Li JJ, He JG, Nan JL, Guo YL, Xiong CM.
    Cardiovasc Ther; 2010 Apr 15; 28(1):8-14. PubMed ID: 20074254
    [Abstract] [Full Text] [Related]

  • 19. Regulation of peroxisome proliferator-activated receptor β/δ expression and activity levels by toll-like receptor agonists and MAP kinase inhibitors in rat astrocytes.
    Chistyakov DV, Aleshin S, Sergeeva MG, Reiser G.
    J Neurochem; 2014 Aug 15; 130(4):563-74. PubMed ID: 24806616
    [Abstract] [Full Text] [Related]

  • 20. The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells.
    Alvarez-Guardia D, Palomer X, Coll T, Davidson MM, Chan TO, Feldman AM, Laguna JC, Vázquez-Carrera M.
    Cardiovasc Res; 2010 Aug 01; 87(3):449-58. PubMed ID: 20211864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.